Business Wire

CORSEARCH

17.5.2024 00:01:38 CEST | Business Wire | Press release

Share
Trade in Counterfeit Goods Market Set to Reach €1.67 Trillion in 2030 – Corsearch

Corsearch, leading provider of brand protection and trademark solutions, has today shared research predicting that the size of the global trade in counterfeit goods could reach €1.67 trillion by 2030, a 75% increase from that of 2023 and a growth 3.6 times higher than predicted for the global economy over the same period.1

Corsearch calculations estimate that counterfeits accounted for 3.3% of global trade in 2023, and will grow to 5% by 2030 - meaning €1 in every €20 spent globally on products could be spent on counterfeit goods.

The total displaced economic activity from counterfeiting in 2022 – namely the cost to brands and manufacturers – totalled €1.02 trillion, resulting in a loss of €162 billion to worldwide sales tax revenue, impacting up to 5.4m jobs.2

In addition to the negative global economic impact of counterfeiting, fake products have a damaging effect on the reputation of brands, reducing customer trust and risking consumer safety.

Corsearch has recognised the need for advanced innovations and solutions in brand protection to meet this challenge, and has today launched its latest technology platform, Corsearch Zeal. The platform uses AI to secure removal of fakes and counterfeit goods from the Internet whilst enabling Corsearch’s team of experts to focus on the most severe issues for brands and consumers and to find the source of the illicit activity.

Using the Corsearch Zeal platform, brands can go further to identify the source of the problem, reducing the losses and harm from counterfeit trade and protecting consumers.

Simon Baggs, President of Brand & Content Protection, Corsearch, commented:

"The rapid expansion of the counterfeiting industry could take up to 5% of the global goods economy by 2030 - posing a significant threat to brands. Urgent measures need to be taken, which is why we are today launching our new Corsearch Zeal platform. Technology enables vast swathes of data to be collated – enabling brands to collaborate to stop online sales whilst also targeting the source of the problem. Without this effort, we estimate that one in twenty euros will be spent on counterfeit goods by 2030, a worrying figure for brands already grappling with the problem in 2024.

“Corsearch Zeal shows our continued dedication to innovation and delivering unrivalled brand protection in the face of this escalating challenge. With Corsearch Zeal and our team of experts, we want to provide the most advanced solutions, enabling brands to work together to protect their consumers.”

For further information on Corsearch Zeal, read more here.

Notes to Editors

Methodology

Corsearch calculations are based on the below datapoints:

  1. Total global trade in goods: $31 trillion (UN Conference on Trade & Development) (2023)
    Total growth in global trade in goods through 2030: 2.3% (Boston Consulting Group)
    Total trade in counterfeit goods, 2023: $1.023 trillion (OECD data) (2023)
  2. Employment loss: 4.2-5.4 million jobs (Frontier Economics)
    Cost of displaced legitimate economic activity due to counterfeiting: $1,106 billion (Frontier Economics & Corsearch calculation) (2022)
    Impact on sales tax revenue: $174 billion (Frontier Economics & Corsearch calculation)
  3. 8.3% CAGR in counterfeit trade (Corsearch calculation, based on data from UN Conference on Trade & Development, OECD and EUIPO figures)

For currency conversion into EUR, FX Rates accurate as of 09/05/24

About Corsearch:

Corsearch’s leading Trademark and Brand & Content Protection Solutions are revolutionizing how companies create, monitor, and protect their brands. Over 5,000 businesses worldwide partner with Corsearch to safeguard consumers and their trust in brands — preventing confusion, misrepresentation, and fraud using the hybrid intelligence of advanced AI precision and expert decision of human analysts.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240515226927/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release

Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release

MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release

Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye